RT Journal Article
SR Electronic
T1 The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 363
OP 371
DO 10.21873/anticanres.15494
VO 42
IS 1
A1 EUN JI LEE
A1 SOO JIN PARK
A1 JEESUN LEE
A1 JAEHEE MUN
A1 HAERIN PAIK
A1 AERAN SEOL
A1 JUNHWAN KIM
A1 GA WON YIM
A1 SEUNG-HYUK SHIM
A1 HEE SEUNG KIM
A1 SUK-JOON CHANG
A1 on behalf of the KoRIA Trial Group
YR 2022
UL http://ar.iiarjournals.org/content/42/1/363.abstract
AB Background/Aim: To evaluate the clinical desire for pressurized intraperitoneal aerosol chemotherapy (PIPAC) in South Korea. Patients and Methods: We performed an online survey on surgical oncologists between November and December 2019 using a questionnaire consisting of 20 questions. Results: A total of 164 respondents answered the questionnaire. Among those specialized in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma 41.7-50% preferred PIPAC for the curative treatment of primary diseases, whereas 32.7-33.3% majoring in colorectal and hepatobiliary cancers chose it for the palliative treatment of recurrent diseases. Furthermore, 66.7-95.2% considered PIPAC appropriate for the cancers they specialized in, and 76-78.7% expected a treatment response of more than 50% and considered grade 1 or 2 complications acceptable. Most respondents answered the reasonable costs to purchase and implement PIPAC once at between 1,000,000-5,000,000 South Korean Won (KRW). Conclusion: Most Korean surgical oncologists expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.